Is Remicade (infliximab) appropriate for treating Behçet’s disease, and what are the recommended dosing and monitoring guidelines?

Remicade (Infliximab) for Behçet's Disease

Infliximab is highly appropriate and effective for treating Behçet's disease, particularly for severe refractory ocular disease, gastrointestinal involvement, vascular disease, and neurological manifestations that have failed conventional immunosuppressive therapy.

Primary Indications for Infliximab in Behçet's Disease

Severe Ocular Disease (Strongest Evidence)

For patients with severe eye disease—defined as >2 lines drop in visual acuity on a 10/10 scale and/or retinal disease (retinal vasculitis or macular involvement)—infliximab should be used in combination with azathioprine and corticosteroids 1. This represents a guideline-level recommendation from EULAR.

The evidence supporting this is robust:

• Complete remission achieved in 30-85.7% of patients with Behçet's-associated uveitis 2
• 76.7% showed good response with significant decrease in uveitis attacks 2
• Visual acuity improvements were statistically significant 2
• More rapid reduction in inflammation (2 weeks) compared to alternatives 2
• 92% of patients showed improvement or some improvement at 1 year, with 44% having no ocular attacks during the year 3
• Quality of life improvements were significant 2

Infliximab can be considered as a first-line immunomodulatory agent for ocular manifestations of Behçet's disease 4, representing a shift from traditional stepwise therapy in severe cases.

Gastrointestinal Involvement

For moderate-to-severe intestinal Behçet's disease refractory to conventional therapy, infliximab should be tried before surgery except in emergencies 1. TNF-α antagonists are specifically mentioned as agents to attempt before surgical intervention 1.

Recent high-quality evidence demonstrates:

• 93.9% clinical response rate with significant DAIBD score reduction (mean change 50.5 points at week 8,61.5 points at week 32) 5
• 92.3% maintained clinical response at week 32 5
• Well-tolerated with no severe adverse reactions in this phase 3 study 5

Vascular Involvement

For vascular Behçet's disease, infliximab is effective and should be considered for patients refractory to conventional immunosuppressives 1. While guidelines note "no firm evidence" for major vessel disease management, they explicitly list TNF-α antagonists as agents to try 1.

Recent evidence shows:

• 73% remission rate at 6 months, 63% at 12 months 6
• Particularly effective for pulmonary artery involvement and venous thrombosis 6
• Allows significant corticosteroid reduction or discontinuation 7, 6
• 17 of 18 patients achieved remission in one series 7

Neurological Involvement

For parenchymal neuro-Behçet's disease, TNF-α antagonists including infliximab should be tried when conventional therapy fails 1.

Critical timing consideration: Functional disability grades after infliximab treatment correlate significantly with the interval from onset to infliximab initiation 8. Therefore, infliximab should be administered as soon as possible for chronic progressive neuro-Behçet's disease patients with inadequate responses to methotrexate 8.

Dosing Regimen

Standard dosing: 5 mg/kg intravenously at weeks 0,2, and 6 (induction), followed by 5 mg/kg every 8 weeks (maintenance) 5. This is the regimen used in the phase 3 intestinal Behçet's trial and aligns with dosing for other inflammatory conditions 9.

Note: While infliximab is not FDA-approved specifically for Behçet's disease 9, it is approved for other inflammatory conditions including Crohn's disease and ulcerative colitis at this same dosing.

Combination Therapy vs. Monotherapy

For ocular disease, infliximab should be combined with azathioprine and corticosteroids 1. This is the guideline-recommended approach.

However, infliximab monotherapy can be effective and is not inferior to combination therapy over 10-year follow-up 10. In this study, 70.3% continued infliximab for 10 years with equivalent outcomes between monotherapy and combination therapy groups 10.

Monitoring and Safety

Pre-treatment Screening

Screen for tuberculosis before initiating infliximab and periodically during therapy 9. This is critical as endemic areas for Behçet's overlap with TB-endemic regions 1.

Therapeutic Drug Monitoring

Serum infliximab concentrations correlate significantly with effectiveness in resolving recurrent uveitis episodes 11. Mean concentrations: 117.4 μg/ml at Day 0,11.4 μg/ml at Week 4, and 6.3 μg/ml at Week 8 11. Monitoring can guide dose adjustments.

Safety Profile

• Non-serious infections occur in 13.2% of patients 12
• Infusion reactions in 2.9% 12
• Serious adverse events in 2.9% 12
• 46% experienced adverse effects during first year, but most were non-serious 3
• Important: Loss of response and adverse events typically occur during the initial 5-year period; safe and effective continuation can be expected thereafter 10

Critical Safety Warnings

• Risk of lymphoma and other malignancies, particularly hepatosplenic T-cell lymphoma in young males receiving concomitant azathioprine or 6-mercaptopurine 9
• Ensure appropriate personnel and medication available to treat infusion reactions 9
• Administer over at least 2 hours with an in-line filter 9

Common Pitfalls to Avoid

1. Delaying infliximab introduction: For neuro-Behçet's, delayed introduction leads to irreversible functional disability 8
2. Using etanercept instead: Etanercept shows no evidence of benefit in non-anterior uveitis and may paradoxically worsen uveitis 2
3. Stopping too early: Although relapses can occur, particularly with solo use, many patients achieve sustained remission with continued therapy 1
4. Inadequate TB screening: Critical given geographic overlap of Behçet's and TB endemic areas 1
5. Ignoring the need for anticoagulation: Anticoagulants are NOT recommended for venous thrombosis in Behçet's due to risk of fatal bleeding from coexisting arterial aneurysms 1. Immunosuppression is the primary treatment 1

Treatment Algorithm by Manifestation

Ocular (posterior segment):

• First-line: Azathioprine + corticosteroids
• Severe disease: Add infliximab 5 mg/kg (0,2,6 weeks, then every 8 weeks)

Gastrointestinal:

• Try sulfasalazine, corticosteroids, azathioprine first
• Refractory disease: Infliximab 5 mg/kg (0,2,6 weeks, then every 8 weeks)

Vascular:

• Immunosuppressives (corticosteroids, azathioprine, cyclophosphamide, or cyclosporine)
• Refractory disease: Infliximab 5 mg/kg (0,2,6 weeks, then every 8 weeks)

Neurological:

• Parenchymal: Try corticosteroids, IFNα, azathioprine, cyclophosphamide, or methotrexate
• Inadequate response: Add infliximab immediately to prevent irreversible disability